EM@3AM: Immune-Related Adverse Event from Immune Checkpoint Inhibitors
A 43-year-old female with a history of breast cancer presents to the ED with diffuse abdominal pain and diarrhea for one week. She is experiencing over 12 episodes of non-bloody diarrhea daily. She is currently receiving Atezolizumab (Tecentriq) for breast cancer. Vital signs include BP 82/43, HR 121, T 98F oral, RR 22, SpO2 98% on RA. She appears tired, and her oral mucosa are dry. She displays diffuse abdominal tenderness to palpation, but there is no evidence of peritonitis. What is the patient’s diagnosis?
EM@3AM: Immune-Related Adverse Event from Immune Checkpoint Inhibitors Read More »